Abstract
Objective In this study, we investigate the impact of cigarette smoking on airway inflammation and the effect on responses to treatment with inhaled eortieosteroids （ICS） in patients with bronchial asthma （asthma）. Methods 38 outpatients with chronic stable asthma who visited from December 2009 to January 2011 were enrolled in the study. 23 cases were nonsmokers and 15 cases were smokers. All of them were treated by daily inhaled budesonide,and 132 agonist when necessary. They were required to record symptoms and peak expiratory flow every day on an asthmatic diary card. The patients were followed 28 days, ACT score, asthma symptom score, asthma control test （ACT） score, pulmonary function,and peak expiratory flow were compared between non-smoking and smoking asthmatic patients. Induced sputum eosinophil and neutrophil proportion, and examined the levels of interleukin-8 （IL-8） and eotaxin in induced-sputum by enzymatic immunoassay （ELISA）. Results All of the patients had statistically significant increases in ACT score （ F = 39. 991, P 〈0.05）, mean morning and night PEF, FEV1% pred （ F = 56. 075, P 〈0.05）, PEFM pred （ F = 53. 535, P 〈 0.05）, eosinophil proportion （ F = 15. 271, P d0.05） and eotaxin （ F = 24. 172, P 〈0.05）, and a significant decrease in asthma-symptom score after budesonide treatment compared with before. While there were significantly greater changes in any of these parameters in non-smokers than in smokers （ P 〈0.05）. Conclusions Active cigarette smoking impairs the efficacy of short term inhaled corticosteroid treatment in asthma. This finding has important implications for the management of patients with asthma who smoke. Key words: Asthma ; Smoking ; Inhaled corticosteroid ; Lung function ; Airway inflammation
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call